New 'Living Drug' trial offers hope for Tough-to-Treat lymphoma
NCT ID NCT07271121
Summary
This study is testing a one-time treatment called MB-CART19.1, which uses a patient's own modified immune cells, in adults whose non-Hodgkin lymphoma has returned or not improved with standard therapies. The main goal is to see if this cell therapy can shrink or eliminate the cancer and to monitor its safety. Participants will receive a single infusion and be followed closely for one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
King Hussein Cancer Center
RECRUITINGAmman, 11941, Jordan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.